Paper Details

  1. Home
  2. Paper Details

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

Author: , ArcherDavid F, AyotteNormand, BalserJohn, BaronMira, BeauregardAdam, BlouinFrançois, BouchardCéline, CusanLeonello, CôtéIsabelle, GallagherJohn C, GirardGinette, KoltunWilliam, LabrieClaude, LabrieFernand, LavoieLyne, MartelCéline, MoyneurÉrick, PortmanDavid J, WaldbaumArthur S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Daily intravaginal administration of 0.5% DHEA (prasterone) for 52 weeks improved moderate to severe (MS) symptoms and signs of vulvovaginal atrophy (VVA) in postmenopausal women. The severity of the VVA symptoms examined in detail in the different groups.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: An objective was to analyze the time course of efficacy of daily intravaginal administration of 0.5% (6.5mg) DHEA (prasterone) for 52 weeks on the moderate to severe (MS) symptoms and signs of vulvovaginal atrophy (VVA). METHOD: Five hundred twenty-one postmenopausal women were enrolled ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.maturitas.2015.02.005

データ提供：米国国立医学図書館（NLM）

A Oasis in the Desert of Menopause: Prasterone for Vulvovaginal Atrophy

Menopause, a natural transition in a woman's life, can sometimes bring unwelcome symptoms. Vulvovaginal atrophy (VVA), a condition affecting the vaginal tissues, can be a particularly uncomfortable experience. This research delves into the potential benefits of prasterone (DHEA), a naturally occurring hormone, in addressing the symptoms of VVA, offering a glimmer of hope in this challenging desert.

A Potential Solution for a Common Issue

The researchers found that daily intravaginal administration of prasterone was effective in improving the symptoms of VVA, including dyspareunia (painful intercourse), vaginal dryness, and irritation/itching. This finding is particularly encouraging, as VVA is a common condition that can significantly impact a woman's quality of life. Prasterone emerges as a potential oasis in the desert of menopause, offering relief from these uncomfortable symptoms.

Navigating the Desert of Menopause with Greater Comfort

This research highlights the importance of finding solutions for the various challenges that women face during menopause. By addressing the symptoms of VVA, prasterone has the potential to improve the overall well-being of women during this transition, allowing them to navigate this desert with greater comfort and confidence.

Dr.Camel's Conclusion

This research provides a valuable reminder that even in the harsh desert of menopause, there are solutions to improve a woman's well-being. By exploring the potential benefits of prasterone for VVA, we can offer women a more comfortable and fulfilling journey through this natural transition. This research emphasizes the importance of finding solutions for the diverse challenges women face, offering a beacon of hope in the desert of menopause.

Date :
  1. Date Completed 2016-03-31
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25771041

DOI: Digital Object Identifier

10.1016/j.maturitas.2015.02.005

Related Literature

Article Analysis
・Effects of prasterone vaginal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.